Haemonetics Stock: Plasma Thesis Continues, Reiterate Buy (NYSE:HAE)
urzine Investment Summary We reiterate the buy thesis on Haemonetics Corporation (NYSE:HAE) following second quarter earnings and an extended outlook for plasma collections in FY23. We advocated the investment debate hinges on this point for […]
